Top

The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension

Active

75N98026R00085Federal

Response Deadline09/21/2026, 04:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The National Institutes of Health intends to negotiate a sole-source contract with the University of Illinois at Chicago for preclinical animal research services. The project focuses on evaluating the therapeutic effects of soluble adenylyl cyclase inhibition on pulmonary arterial hypertension using a specific endothelial cell-specific Cav1 knockout murine model. The University of Illinois at Chicago is identified as the sole source because it maintains the necessary mouse colony required for the study, which is not known to be available at other laboratories. This special notice, identified by solicitation number 75N98026R00085, is not a request for competitive quotations, though interested responsible sources may submit capability statements for consideration. The performance of the research will take place in Chicago, Illinois. The response deadline for any interested parties to submit documentation is September 21, 2026.

General Info

NIH sole-source contract with UIC for pulmonary arterial hypertension preclinical animal research.

Agency

Department Of Health And Human Services → National Institute Of Health Nih-OdView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Chicago, IL, 60607, USA

Set-Aside

NONE

Documents

(1)

Notice of Intent to Sole Source - Therapeutic Role of Soluble Adenylyl Cyclase Inhibition

PDF•sources-sought

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PostedSep 13

special-notice

Response DeadlineSep 21

Submission deadline

Response Deadline

09/21/2026, 04:00:00 PM UTCin 7 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institute Of Health Nih-Od

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institute Of Health Nih-Od

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Donna Cornish

contact@example.gov

Full Description

The National Institutes of Health (NIH) intends to negotiate on a sole-source basis with the University of Illinois at Chicago (UIC) for preclinical animal research services to evaluate the therapeutic effects of soluble adenylyl cyclase (sAC) inhibition on pulmonary arterial hypertension (PAH) using an established endothelial cell-specific Cav1 knockout (EC-Cav1 KO) murine model and corresponding wild-type controls.

The Government intends to solicit from a single source pursuant to FAR 13.106-1(b)(1). UIC currently maintains the established EC-Cav1 KO mouse colony required for this study, and the model is not known to be maintained by another laboratory.

This notice of intent is not a request for competitive quotations. However, all responsible sources that believe they can satisfy the Government's requirements may submit a capability statement and/or quotation for consideration by the Government.

Please see the attached Notice of Intent to Sole Source for the complete description of the requirement, basis for the intended sole-source acquisition, response instructions, and applicable response deadline.